1 Peak plasma concentrations achieved at approximately 3.5 hours after oral administration. Myrbetriq® (mirabegron) is a prescription medicine for adults used to treat overactive bladder (OAB) with symptoms of urgency, frequency and leakage. taken, how much, and when it happened. Myrbetriq should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB, including solifenacin succinate.Angioedema of the face, lips, tongue and/or larynx has been reported with Myrbetriq and with solifenacin succinate. If a patient experiences these effects, dose reduction or drug discontinuation should be considered.Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co-administered with Myrbetriq. Mirabegron belongs to the family of medications called This medication works by relaxing the bladder muscles. Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co‑administered with Myrbetriq. Drug interaction studies were conducted to investigate the effect of co-administered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of co‑administered drugs. Myrbetriq is not for everyone. If you miss several doses, talk to your doctor. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect. If you miss a dose, skip the missed dose and continue with your regular dosing schedule. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). This helps to increase how much urine the bladder can hold and to reduce the involuntary loss of urine, the urge to pass urine, and the frequency of urination.Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. Symptoms can include:Call 911 or go to the nearest emergency room if you develop these symptoms.You shouldn’t take this drug if you have severe liver disease. However, many people have no side effects or only have minor side effects. The information contained on Astellas Medical Information is intended for U.S. healthcare professionals only.This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a registered trademark of Astellas Pharma Inc.I further certify that my participation in this program is consistent with all applicable state laws and any obligations, contractual or otherwise, that I have as a pharmacy provider. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq and solifenacin succinate should still be administered with caution to patients with clinically significant BOO. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. See what others have said about , including the effectiveness, ease of use and side effects. The study is created by eHealthMe based on reports of 782 people who take Myrbetriq and Metformin from the Food and Drug Administration (FDA), and is updated regularly. Administration to pregnant animals during organogenesis resulted in reversible skeletal variations (in rats) at 22-fold (via AUC) the maximum recommended human dose (MRHD) of 50 mg/day and decreased fetal body weights (in rabbits) at 14-fold the MRHD If they’re more severe or don’t go away, talk to your doctor or pharmacist.Call your doctor right away if you have serious side effects. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq and solifenacin succinate should still be administered with caution to patients with clinically significant BOO. Use Myrbetriq (mirabegron) as ordered by your doctor. Myrbetriq Drug Information / Drug Summary email print Close window.